NASDAQ · Biotechnology

VRCA (VRCA) Stock

$5.35 +6.57% NASDAQ: VRCA Healthcare

Valuation

MetricValue
Price$5.35
Market Cap$56.99M
P/E Ratio-3.58
P/B Ratio2.56
P/S Ratio1.73
EPS (TTM)$-1.68
52-Week High$9.82
52-Week Low$3.28
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-72.00%
ROA-38.30%
ROCE-48.00%
Gross Margin-33.33%
Operating Margin-33.33%
Net Margin-47.97%
Debt/Equity0.09
Current Ratio2.69

Annual Financials (USD)

Metric20212022202320242025
Revenue$12.0M$9.0M$5.0M$8.0M$36.0M
Operating Profit$-31.0M$-21.0M$-66.0M$-66.0M$-12.0M
Net Profit$-35.0M$-24.0M$-67.0M$-77.0M$-18.0M
EPS$-12.97$-7.17$-14.78$-14.78$-1.68
Op Margin-257.6%-235.8%-1283.3%-871.3%-33.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$80.0M$45.0M$82.0M$54.0M$47.0M
Total Liabilities$48.0M$5.0M$62.0M$64.0M$22.0M
Cash$16.0M$34.0M$70.0M$46.0M$30.0M
Borrowings$43.0M$2.0M$46.0M$46.0M$2.0M

Latest News

Verrica Pharmaceuticals Signs Distribution Deal With Medomie for Molluscum Treatment MT Newswires · Jul 21, 2026 Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel GlobeNewswire · Jul 21, 2026 Verrica Pharmaceuticals' Doses First US Patient in Phase 3 Trial Evaluating Ycanth to Treat Common Warts MT Newswires · Jun 22, 2026 Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts GlobeNewswire · Jun 22, 2026 Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference GlobeNewswire · May 28, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-28.0M$-19.0M$-39.0M$-61.0M$-18.0M
Investing Cash Flow$-2.0M$54.0M$-1.0M$0$0
Financing Cash Flow$1.0M$0$0$0$0
Net Cash Flow$5.0M$19.0M$35.0M$-23.0M$-16.0M
Free Cash Flow$-28.0M$-19.0M$-39.0M$-61.0M$-18.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-22.01%
Quick Ratio1.90
Interest Coverage-1.50
Return 1Y-28.32%
Return 3Y-91.45%
Return 5Y-94.44%

Ownership

Insiders Held48.75%
Institutions Held27.87%
Institutions Float Held54.39%
Institutional HolderSharesReport Date
Caligan Partners, LP923,9102026-03-31
Affinity Asset Advisors, Llc707,3382026-03-31
Cannell Capital LLC685,1232026-03-31
Armistice Capital, LLC518,1812026-03-31
Velan Capital Investment Management LP471,5592026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANTX $4.93 +0.20% -4.76 $177.56M 0.00%
BOLD $2.48 -3.50% -0.56 $55.74M 0.00%
EVAXEvaxion Biotech A/S $3.05 +0.66% -1.99 $19.27M 0.00%
GBIOGeneration Bio Co. $5.34 +0.00% -0.87 $35.98M 0.00%
JSPR $0.63 +1.48% -0.21 $10.24M 0.00%

About VRCA

VRCA is led by CEO Jayson Rieger, employs 71 people, headquartered in US, publicly traded since 2018.

VRCA stock trades at $5.35 with a market capitalization of $56.99M. The stock is valued at a price-to-earnings (P/E) ratio of -3.58, price-to-book of 2.56, price-to-sales of 1.73. Over the past 52 weeks the stock has ranged between $3.28 and $9.82, and currently trades 45.5% below its 52-week high.

On profitability, VRCA generates a return on equity (ROE) of -72.00%, return on capital employed of -48.00%, an operating margin of -33.33%, a net profit margin of -47.97%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides